Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study

Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study

Abstract Aim Sacubitril/valsartan is a first‐in‐class angiotensin receptor‐neprilysin inhibitor developed for the treatment of heart failure with reduced ejection fraction. Its benefits are achieved through the inhibition of neprilysin (NEP) and the specific blockade of the angiotensin receptor AT1....

Full description

Bibliographic Details
Main Authors: Elena Revuelta‐López, Julio Núñez, Paloma Gastelurrutia, Germán Cediel, James L. Januzzi, Nasrien E. Ibrahim, Michele Emdin, Roland VanKimmenade, Domingo Pascual‐Figal, Eduardo Núñez, Frank Gommans, Josep Lupón, Antoni Bayés‐Genís
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:ESC Heart Failure
Subjects:
Heart failure
Neprilysin
Sacubitril/valsartan
Endorphins
α‐Endorphin
γ‐Endorphin
Online Access:https://doi.org/10.1002/ehf2.12607

Internet

https://doi.org/10.1002/ehf2.12607

Similar Items